In our models with higher levels of intrinsic IL6 signaling pathways (30200 and HGS2), we observed this deleterious effect with increase in metastasis and reverting of tumor suppressive immune cell phenotype following cediranib-treatment at endpoint. The gene discussed is IL6; the disease is neoplasm.